Bristol Myers Squibb’s pumitamig (BNT327/BMS986545) combined with chemotherapy generated high response rates in a first-line phase 2 readout from the ROSETTA Lung-02 study. Results presented at the 2026 ASCO Annual Meeting showed an unconfirmed overall response rate of 72.5% and a confirmed ORR of 62.5% across 40 patients. The regimen’s confirmed disease control rate was reported at 100%, with responses across both nonsquamous and squamous NSCLC histologies and across PD-L1 expression strata. Safety updates described an acceptable profile, with no new safety signals; reported grade 3 events included VEGF-related effects and immune-related adverse effects. While the data are early and unconfirmed response measures were also provided, the trial signal expands the set of combination approaches vying for durable activity in metastatic NSCLC and may inform future registrational study design.